Neuropathix, Inc.: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania. | Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania. | ||
__INDEX__ | |||
Latest revision as of 14:34, 14 August 2022
SummaryEdit
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.